Influenza ﹣ FAQ
1. What is influenza?
Influenza is an acute illness of the respiratory tract caused by influenza viruses. It can be caused by various types of influenza viruses. In Hong Kong, the two subtypes of influenza A virus, H1N1 and H3N2, and influenza B virus, are most commonly seen. Influenza occurs in Hong Kong throughout the year, but is usually more common in periods from January to March/April and from July to August. The virus mainly spreads by respiratory droplets. The disease is characterised by fever, sore throat, cough, runny nose, headache, muscle aches and general tiredness. It is usually self-limiting with recovery in two to seven days. However, if persons with weakened immunity and elderly persons get infected, it can be a serious illness and may be complicated by bronchitis, pneumonia, encephalopathy, or even death in the most serious cases. Serious infection or complications can also occur in healthy individuals.
2. What is the difference between seasonal and pandemic influenza?
Seasonal influenza refers to the viruses that circulate in the human population and cause widespread illnesses especially during each influenza season. Pandemic influenza occurs rarely, when a new influenza virus emerges which is markedly different from those already circulating in the human population. It causes disease in people and spreads easily between people because they have little or no immunity to it.
3. Why is seasonal influenza vaccination important?
Seasonal influenza vaccination (SIV) is one of the effective means to prevent seasonal influenza and its complications, as well as reduce influenza related hospitalisation and death.
There is increasing evidence suggesting that a person contracting influenza and COVID-19 at the same time may be more seriously ill and has a higher risk of death, and influenza vaccination may reduce the likelihood of hospitalisation and length of stay. As Hong Kong continues to face the challenge of COVID-19 pandemic, it is important to ensure that people who are at greater risk of influenza infection are prioritized to receive SIV, to prevent the healthcare system from being overwhelmed.
4. If the level of local seasonal influenza activity remains low, why should one be vaccinated against seasonal influenza?
Seasonal influenza activity in Hong Kong remained at a low level since mid-February 2020 and the influenza transmission may have been altered by the range of non-pharmaceutical interventions (e.g. social distancing, hand hygiene, wearing a mask in public) in place for COVID-19, travel restrictions and border closures. However, influenza transmission could increase when these control measures are lifted, leading to potential co-circulation of influenza and SARS-CoV-2, with additional burdens on vulnerable populations and health systems.
Given that influenza vaccines are safe and effective, and severe cases can occur in healthy individuals, all members of the public aged 6 months or above, except those with known contraindications, should receive seasonal influenza vaccination for personal protection.
B. People who should receive seasonal influenza vaccination
1. Who should receive seasonal influenza vaccination?
Given that influenza vaccines are safe and effective and severe cases can occur even in healthy persons, all members of the public aged 6 months or above, except those with known contraindications, should receive seasonal influenza vaccine for personal protection.
2. Who should have higher priority for seasonal influenza vaccination?
People who are in the priority groups are generally at increased risk of severe influenza or transmitting influenza to those at high risk. Therefore, they should have higher priority for seasonal influenza vaccination.
Influenza transmission may have been altered by the range of non-pharmaceutical interventions (NPIs) in place for COVID-19 or travel restrictions or border closures. Influenza transmission could increase when the NPIs and travel restrictions are lifted, leading to potential co-circulation of influenza and COVID-19. WHO has reconsidered the prioritization of risk groups of influenza vaccination during COVID-19 pandemic. They have prioritised health workers and older adults (above age of 65) as the highest priority risk group during the COVID-19 pandemic.
In the 2022-23 season, the Scientific Committee on Vaccine Preventable Diseases (SCVPD) recommended the following priority groups for seasonal influenza vaccination in Hong Kong:
* People with chronic medical problems mainly refer to those who have chronic cardiovascular (except hypertension without complication), lung, metabolic or kidney diseases, obesity# (Body mass index [BMI] 30 or above), who are immunocompromised^, children and adolescents (aged 6 months to 18 years) on long-term aspirin therapy, and those with chronic neurological condition that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration or those who lack the ability to care for themselves.
# Obesity is considered as an independent risk factor for influenza complication and thus people with BMI 30 or above are included in the priority groups for seasonal influenza vaccination.
^ People who are immunocompromised refer to those with a weakened immune system due to disease (such as HIV/AIDS) or treatment (such as cancer treatment).
3. I do not belong to any recommended priority group for 2021-22 seasonal influenza vaccine. Should I receive 2021-22 seasonal influenza vaccination?
According to the World Health Organization, when the vaccine strains closely match the circulating influenza viruses, efficacy of influenza vaccine in individuals younger than 65 years of age typically range from 70% to 90%. Given that severe cases do occur in previously healthy persons, all members of the public aged 6 months or above, except those with known contraindications, should receive seasonal influenza vaccination for personal protection. Members of the public can consult their family doctors to receive seasonal influenza vaccination for personal protection.
4. Why should pregnant women receive seasonal influenza vaccination?
Influenza vaccination in pregnant women has shown benefits for both mother and child in terms of reduced acute respiratory infections. The World Health Organization considers inactivated influenza vaccine (IIV) to be safe in pregnancy and there is no evidence showing that IIV can cause abnormality in foetus even if given during the first trimester. However, pregnant women should NOT receive live attenuated influenza vaccine because it contains live viruses. Pregnant women should consult a doctor for any queries.
5. Why should obese persons (body mass index [BMI] 30 or above) receive seasonal influenza vaccination?
Local and overseas evidence suggested that obesity is an independent risk factor for severe influenza A(H1N1)pdm09 infection including intensive care unit admission or death. As the influenza A(H1N1)pdm09 virus is a common type of seasonal influenza virus, obese individual with BMI 30 or above is regarded as having a high-risk condition and is therefore recommended for influenza vaccination.
6. Why should persons aged 50 or above receive seasonal influenza vaccination?
The SCVPD recommended seasonal influenza vaccination (SIV) for elderly aged 65 years or above as they pose a higher risk for complications, excess hospital admissions and deaths from influenza. The World Health Organization has recommended older adults as one of the highest priority groups to receive influenza vaccine during the COVID-19 pandemic.
Older adults (persons aged 50 to 64) are also recommended to receive SIV because local influenza epidemiology showed that people aged 50 to 64 years, irrespective of high-risk conditions, were having a higher risk of influenza-related intensive care unit admission and death.
7. Why should healthcare workers (HCWs) receive seasonal influenza vaccination?
The SCVPD recommends HCWs to receive seasonal influenza vaccination to reduce morbidity and hence reduce absenteeism among healthcare workers related to respiratory infections. Seasonal influenza vaccination in HCWs can also reduce the risk of transmitting influenza to patients who are at high risk of complications and mortality from influenza. WHO has recommended healthcare workers as one of the highest priority group to receive influenza vaccine during the COVID-19 pandemic.
8. Why should poultry industry workers receive seasonal influenza vaccination?
PPoultry industry workers have higher chance of contacting avian influenza viruses. Seasonal Influenza vaccination can prevent seasonal influenza in humans, and hence minimise the chance of concomitant infections of human seasonal influenza and avian influenza viruses in humans. This in turn minimises the risk of genetic re-assortment and eventual emergence of a novel influenza A virus.
9. Why should pig farmers and pig-slaughtering industry personnel receive seasonal influenza vaccination?
Researchers previously detected influenza A(H1N1)pdm09 (formerly known as Human Swine Influenza) viruses in pigs sampled in Hong Kong. Local experts considered that the influenza A(H1N1)pdm09 virus detected in pigs was transmitted from humans to pigs. Swine influenza viruses circulating in pigs might infect humans in rare occasions. Seasonal Influenza vaccination of the pig-related industry workers can prevent seasonal influenza among them, and hence minimise the chance of concomitant infections of human seasonal influenza and swine influenza viruses in either humans or pigs. This in turn minimises the risk of genetic re-assortment and eventual emergence of a novel influenza A virus.
10. Why children aged 6 months to 11 years are recommended to receive seasonal influenza vaccination?
Seasonal influenza vaccination is recommended for children 6 months to 11 years for reducing influenza related complications such as excess hospitalisations or deaths. Studies in overseas have shown that vaccinating young school children may potentially reduce school absenteeism and influenza transmission in the community.
C. Seasonal influenza vaccine
1. What is the recommended composition of the 2022-23 seasonal influenza vaccine?
If trivalent influenza vaccine is being used, the influenza B component shall contain a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
2. What types of seasonal influenza vaccines are recommended for use in Hong Kong by SCVPD?
Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) and live attenuated influenza vaccine (LAIV) are recommended for use in Hong Kong by SCVPD. For IIVs, quadrivalent IIV is preferred to trivalent IIV due to the additional protection against one more lineage of influenza B offered by quadrivalent IIV. Depending on individual brand, most IIVs are recommended for use among people six months of age or older, including those who are healthy, pregnant women and those with chronic medical problems. RIV is recommended for use in individuals of 18 years of age or above. For LAIV, which is a quadrivalent vaccine, it can be used for people 2 to 49 years of age except those who are pregnant, immunocompromised or with other contraindications (please refer to Question 6 for details). The package inserts for individual products should always be referred to when deciding which vaccine to give.
3. What are the differences among inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) and live attenuated influenza vaccine (LAIV)?
The IIV contains inactivated (killed) viruses. RIV contains haemagglutinin (a surface protein of influenza virus) that is produced by recombinant technology, and does not require egg or influenza virus in the production process. Both IIV and RIV are given by injection. LAIV contains weakened viruses and is given by intranasal spray. IIV, RIV and LAIV are effective, but there are some differences in their indications. Depending on individual product, most IIVs are recommended for use among persons aged 6 months or above, including those who are healthy, pregnant women and those with chronic medical problems. RIV is recommended for use in individuals of 18 years of age or above. LAIV can be used for people 2 to 49 years of age except those who are pregnant, immunocompromised or with other contraindications (please refer to Question 6 for details). Please consult your doctor for details.
4. Who should not receive inactivated influenza vaccine (IIV)?
People who have a history of severe allergic reaction to any vaccine component or a previous dose of any influenza vaccine are not suitable to have inactivated seasonal influenza vaccination. Individuals with mild egg allergy who are considering an influenza vaccination can be given IIV in primary care setting. Individuals with a history of anaphylaxis to egg should have seasonal influenza vaccine administered by healthcare professionals in appropriate medical facilities with capacity to recognise and manage severe allergic reactions. Influenza vaccine contains ovalbumin (an egg protein), but the vaccine manufacturing process involves repeated purification and the ovalbumin content is very low. Even people who are allergic to eggs are generally safe to receive vaccination. Those with bleeding disorders or on anticoagulants should consult their doctors for advice. If an individual suffers from fever on the day of vaccination, vaccination should be deferred till recovery.
5. Who should not receive recombinant influenza vaccine (RIV)?
RIV is recommended for use in individuals of 18 years of age or above. People who have a history of hypersensitivity to any vaccine component of the RIV are not suitable to receive RIV. RIV contains no egg protein.
Those with bleeding disorders or on anticoagulants should consult their doctors for advice. If an individual suffers from fever on the day of vaccination, vaccination should be deferred till recover. Please consult your doctor for details. RIV does not require egg in the production process.
6. Who should not receive live attenuated influenza vaccine (LAIV)?
LAIV is a live vaccine and is generally contraindicated in the following conditions, taking reference from recommendations of the United States, United Kingdom and Canada:
** The UK recommended the use of IIV instead of LAIV for children with increased wheezing and/or needed additional bronchodilator treatment in previous 72 hours. Also, specialist advice should be sought on giving LAIV for children who require regular oral steroid for maintenance of asthma control or who have previously required intensive care for asthmatic attack. Canada recommended that individuals with severe asthma (currently on oral or high-dose inhaled glucocorticosteroids or active wheezing) or those with medically attended wheezing in the 7 days prior to vaccination should not use LAIV.
# According to Canadian guidelines, intramuscular influenza vaccination is the standard for children living with HIV. LAIV may be considered as an option for children 2 to 17 years of age with stable HIV infection on highly active antiretroviral therapy (HAART) and adequate immune function, and the decision should be made on a case-by-case basis.
Individuals with mild egg allergy who are considering an influenza vaccination can be given LAIV in primary care setting. Individuals with a history of anaphylaxis to egg should have seasonal influenza vaccine administered by healthcare professionals in appropriate medical facilities with capacity to recognise and manage severe allergic reactions. Influenza vaccine contains ovalbumin (an egg protein), but the vaccine manufacturing process involves repeated purification and the ovalbumin content is very low. Even people who are allergic to eggs are generally safe to receive vaccination. Please consult your doctor for details.
7. My child has asthma. Should he avoid influenza vaccination in case it gives him an asthmatic attack?
Children suffering from lung diseases such as asthma are recommended to receive IIV because of an increased risk of complications associated with influenza. However, children 2 years through 4 years who have asthma or who have had a history of wheezing in the past 12 months should not receive live attenuated influenza vaccine (Please refer to Question 6 for details).
8. What are the possible side effects following inactivated influenza vaccine administration?
Inactivated influenza vaccine is very safe and usually well tolerated apart from occasional soreness, redness or swelling at the injection site. Some recipients may experience fever, muscle pain, and tiredness beginning 6 to 12 hours after vaccination and lasting up to two days. If fever or discomforts persist, please consult a doctor. Immediate severe allergic reactions like hives, swelling of the lips or tongue, and difficulties in breathing are rare and require emergency consultation.
Influenza vaccination may be rarely followed by serious adverse events such as Guillain-Barré Syndrome (GBS) (1 to 2 cases per million vaccinees) and severe allergic reaction (anaphylaxis) (9 per 10 million doses distributed). However, influenza vaccination may not necessarily have causal relations with these adverse events. Studies have shown that the risk of GBS after influenza infection (17.20 per million infected persons) is much higher than after influenza vaccination (1.03 per million vaccine recipients).
(The Lancet Infectious Diseases. 2013 Sep; 13(9): 769-76)
9. What are the possible side effects following recombinant influenza vaccine (RIV) administration?
The most common side effects following RIV administration include tenderness and pain over the injection site. Recipients may also experience headache, fatigue, muscle pain and joint pain.
10. What are the possible side effects following live attenuated influenza vaccine (LAIV) administration?
Overseas studies and clinical experience had generally indicated LAIV to be a safe vaccine, providing comparable protection against influenza to that afforded by inactivated influenza vaccine (IIV). The most common adverse reactions following LAIV administration are nasal congestion or runny nose (in all ages), fever (in children) and sore throat (in adults). The safety in pregnant women has not been established. Children aged below five years with recurrent wheezing or persons of any age with asthma may be at an increased risk of wheezing following administration.
11. What is Guillain-Barré syndrome (GBS)? Can influenza vaccination cause GBS?
GBS is a rare neurological disorder causing paralysis and even respiratory difficulties. Most people recover completely but some have chronic weakness. GBS can develop following a variety of infections, including influenza. So far, there is no conclusive evidence supporting a causal relationship between seasonal influenza vaccine and GBS.
12. Can I receive seasonal influenza vaccine if I had history of Guillain-Barré syndrome (GBS)?
As it is unknown whether seasonal influenza vaccination is causally associated with increased risk of recurrent GBS, precaution should be made to ascertain the temporal relationship if there is a history of GBS. Please consult your doctor for advice.
13. Does seasonal influenza vaccine cause influenza?
The viruses in inactivated influenza vaccine are killed viruses, therefore cannot cause influenza. The viruses in live attenuated influenza vaccine (LAIV) are weakened and cannot cause influenza in immunocompetent individuals. However, LAIV is not recommended for close contacts and caregivers of severely immunosuppressed persons who require a protective environment because of the theoretical risk of transmission of the live attenuated vaccine viruses to the severely immunosuppressed persons and cause disease.
14. Is the seasonal influenza vaccine safe for breastfeeding mothers and their infants?
Yes. Seasonal influenza vaccine is safe for breastfeeding mothers and their infants. Women who receive the influenza vaccination while pregnant or breastfeeding can develop antibodies against influenza that can be passed to their infants through their breast milk and provide some protection against influenza for infants.
15. Do the seasonal influenza vaccines in Hong Kong contain a mercuric compound or aluminum?
The seasonal influenza vaccines currently supplied for use in Hong Kong do not contain mercuric compound (e.g. thiomersal) or aluminum.
D. Vaccine administration
1. Does the seasonal influenza vaccine work right away?
No. It takes about two weeks after vaccination for antibodies to develop in the body and provide protection against influenza virus infection. For prevention against influenza, vaccinated individuals should maintain good personal and environmental hygiene practices, balanced diet, regular exercise, adequate rest and no smoking.
2. When should I get vaccinated?
Since it takes about two weeks after vaccination for antibodies to develop in the body and provide protection against influenza virus infection, it is advised to get vaccinated at least two weeks before the arrival of winter influenza season, which usually begin in January in Hong Kong. However, even if seasonal influenza vaccination is not received before the winter influenza season, it can still be received as soon as possible.
3. How much protection does the seasonal influenza vaccine provide?
According to the World Health Organization, when the vaccine strains closely match the circulating influenza viruses, efficacy of inactivated influenza vaccine (IIV) in individuals younger than 65 years of age typically range from 70% to 90%. For live attenuated influenza vaccine (LAIV), overseas studies and clinical experience had generally indicated LAIV provides comparable protection against influenza to that afforded by IIV.
4. How long does the protection seasonal influenza vaccine last? Is it necessary to get vaccinated against seasonal influenza every year?
The immunity built up in a vaccinated person in the prior season will decrease over time and may become too low to provide protection in the next season. Since the circulating seasonal influenza strains may change from time to time, the seasonal influenza vaccine composition is updated every year in accordance with the circulating strains to enhance protection. In addition, the vaccine compositions of upcoming seasonal influenza vaccine may be different from previous seasons.
5. How many doses of seasonal influenza vaccine (SIV) will my child need?
To ensure adequate immunity against seasonal influenza, children under 9 years of age who have never received any seasonal influenza vaccination before are recommended to receive 2 doses of SIV with a minimum interval of 4 weeks in the 2021-22 season. Children below 9 years of age who have received at least one dose of SIV before are recommended to receive one dose of SIV in the 2021-22 season. For persons aged 9 years or above, only one dose of SIV is required in each influenza season.
6. If a child under the age of 9 years is getting seasonal influenza vaccination for the first time and requires 2 doses, does the same type of vaccine have to be used for both doses?
No, the first and second doses do not have to be the same type. However, the two doses should be separated by at least 4 weeks.
7. Can pneumococcal vaccines be given together with seasonal influenza vaccine?
Yes. Pneumococcal vaccine can be given with seasonal influenza vaccine at the same clinic visit, but should be administered with a different syringe and at a different injection site if inactivated influenza vaccine is used.
8. Can seasonal influenza vaccine be given together with Measles, Mumps and Rubella (MMR) vaccine?
Yes. Seasonal influenza vaccine can be given with MMR vaccine at the same clinic visit. For individuals receiving inactivated influenza vaccine (IIV), or recombinant influenza vaccine (RIV), they may be administered on the same day or at any interval with MMR vaccine, and those vaccines should be administered with a different syringe and at a different injection site than that of MMR vaccine. For individuals receiving live attenuated influenza vaccine, MMR vaccine should be administered at least four weeks apart.
9. Can my child receive the seasonal influenza vaccination if he / she has received / will receive other immunisation?
Inactivated influenza vaccine (IIV) can be given at the same time or at any time before or after other inactivated vaccine (e.g. Hepatitis B vaccine, but do not include COVID-19 vaccines) or live vaccine (e.g. Measles, mumps and rubella vaccine). Different vaccines should be given at different injection sites if IIV and other vaccines are given at the same time. For individuals receiving live attenuated influenza vaccine, other live vaccines not administered on the same day should be administered at least four weeks apart.
10. Why do some people who have been vaccinated with seasonal influenza vaccine (SIV) still get influenza / influenza-like illness?
There are several reasons why someone may get influenza / influenza-like illness even after they have been vaccinated. Firstly, because the body takes about 2 weeks to develop antibodies after vaccination. If a person is infected with influenza virus shortly after vaccination, he or she may develop influenza before becoming immune. Secondly, infection of viruses other than influenza virus can also result in illness similar to influenza, so people may falsely think that they had influenza despite being vaccinated. Thirdly, small number of people experience side effects after receiving inactivated influenza vaccine, for example fever and myalgia, which may be confused with influenza virus infection. Lastly, SIVs is unable to provide complete protection against influenza, because vaccine effectiveness depends on factors including the similarity between the virus strains present in the vaccine and those circulating in the community, as well as the characteristics of recipients, for example, age. Even so, all members of the public except those with known contraindications should receive SIV annually because influenza vaccination is one of the effective means in reducing the risk of influenza and its complications together with reduction in influenza-associated hospitalisation and death.
11. Can COVID-19 vaccine be given together with seasonal influenza vaccine (SIV)?
COVID-19 vaccines can be co-administered with, or at any time before or after, seasonal influenza vaccine (including inactivated influenza vaccine, live attenuated influenza vaccines and recombinant influenza vaccine) under informed consent. If clients / parents of children wish to space out COVID-19 vaccine with live attenuated vaccines (e.g. Measles, Mumps, Rubella & Varicella (MMRV) Vaccine; Live Attenuated Influenza Vaccine (LAIV)), an interval of 14 days is sufficient.
Source: Centre for Health Protection
last update：9 Sept 2022
HOME | About Us | Health Check | Vaccination | Other Service
Copyright © 2018 毅力醫護健康集團 Kinetics Medical & Health Group 版權所有 不得轉載